Please login to the form below
Triple negative breast cancer
This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... The therapy is now indicated as monotherapy for the treatment of adults with unresectable (cannot be removed by
Latest news
-
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... TNBC is an aggressive and hard-to-treat subtype of
-
Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial
The HER-Vaxx jab is a B-cell activating cancer immunotherapy designed to target tumours that overexpress the HER2/neu receptor in gastric, breast, ovarian, lung and pancreatic cancers. ... Elsewhere in Imugene’s pipeline are a phase 1 triple negative
-
New trial data for Keytruda in triple-negative breast cancer
triple-negative breast cancer (TNBC) following a recent US Food and Drug Administration (FDA) rejection in this indication. ... TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide,
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics is also developing a potential preclinical therapeutic in-house – ENV-0205 – for the treatment of triple-negative breast cancer (TNBC). ... This programme came from Envisagenics’ identification of a splicing error that occurs in TNBC,
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... Triple negative breast cancer is known to be particularly aggressive and fast growing, and after treatment the risk of recurrence is faster and higher than in any other
More from news
Approximately 9 fully matching, plus 72 partially matching documents found.
Latest Intelligence
-
Patient diversity in clinical trials needs to be centre stage
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
-
Cortellis Drugs to Watch in 2020 report
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
-
Pharma deals during February 2014
awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
July 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Novo Nordisk growth takes a hit with China deal
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck enters agreement with Hanmi for investigational NASH drug
- Booster plans expanded to combat Omicron
- US regulators set to approve oral antiviral against COVID-19
- What does the future hold for Light-chain Amyloidosis?
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
